Vision andfocus
The thrust of our mission is to transform patient care through small molecule therapeutics with potential for impact on a global scale.
Vividion Team
Executive Team
Leadership Team
Board Members
Scientific Founders
A legacy of discovery
Vividion Therapeutics is a wholly-owned, independently operated subsidiary of Bayer AG.
Vividion’s roots are in the foundational decades-long research conducted at Scripps Research by a team of scientists led by Professor Ben Cravatt, who together with Professors Phil Baran and Jin-Quan Yu discovered that covalent fragments could be used in a target-agnostic manner to irreversibly bind to shallow protein pockets, thus expanding the universe of potentially druggable targets (disease-causing proteins). Vividion was established to pioneer a covalent-first chemoproteomics approach to identify small molecules that bind currently undrugged targets. Our comprehensive approach spans the full arc of drug development, from screening via our drug discovery platform through therapeutic development in the clinic. The creativity and curiosity that sparked our founding still drive Vividion today and are at the core of everything we do.
Vividion Therapeutics is a wholly-owned, independently operated subsidiary of Bayer AG.